Immuneering (NASDAQ:IMRX) Rating Lowered to Sell at Wall Street Zen

Immuneering (NASDAQ:IMRX) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Saturday.

Several other equities research analysts also recently issued reports on the company. Mizuho set a $12.00 price target on Immuneering in a research report on Wednesday, October 29th. Oppenheimer increased their target price on Immuneering from $21.00 to $30.00 and gave the company an “outperform” rating in a research note on Thursday, September 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immuneering in a report on Monday. Chardan Capital reiterated a “buy” rating and set a $20.00 price target on shares of Immuneering in a report on Thursday, November 13th. Finally, Leerink Partners started coverage on Immuneering in a research report on Friday, October 31st. They issued an “outperform” rating and a $15.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $16.50.

Immuneering Stock Performance

Shares of NASDAQ IMRX opened at $5.65 on Friday. The business’s 50-day simple moving average is $6.45 and its 200-day simple moving average is $5.30. Immuneering has a 52 week low of $1.10 and a 52 week high of $10.08. The firm has a market cap of $364.82 million, a price-to-earnings ratio of -3.17 and a beta of 0.46.

Immuneering (NASDAQ:IMRX) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.01). As a group, equities research analysts forecast that Immuneering will post -1.86 earnings per share for the current year.

Insider Activity

In other news, Director Peter Feinberg bought 7,500 shares of the business’s stock in a transaction that occurred on Friday, October 3rd. The stock was acquired at an average cost of $6.67 per share, for a total transaction of $50,025.00. Following the completion of the purchase, the director owned 156,766 shares of the company’s stock, valued at $1,045,629.22. This trade represents a 5.02% increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders purchased 20,800 shares of company stock worth $143,754 in the last quarter. Insiders own 22.90% of the company’s stock.

Institutional Investors Weigh In On Immuneering

Several institutional investors and hedge funds have recently bought and sold shares of the business. Jane Street Group LLC acquired a new position in shares of Immuneering in the 1st quarter valued at $32,000. China Universal Asset Management Co. Ltd. bought a new stake in Immuneering in the third quarter valued at about $35,000. Future Financial Wealth Managment LLC bought a new stake in Immuneering in the third quarter valued at about $35,000. Kingsview Wealth Management LLC acquired a new position in Immuneering in the second quarter worth about $47,000. Finally, Mercer Global Advisors Inc. ADV bought a new position in Immuneering during the third quarter worth about $70,000. Institutional investors own 67.65% of the company’s stock.

About Immuneering

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.